ALDX

MKT CAP:$93M

Aldeyra Therapeutics, Inc.

Market Cap

$93M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$1.60-$3.07 (-65.74%)

Apr 23, 2026

Company Details

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, wh...

CEO

Todd C. Brady

IPO Date

May 2, 2014

Website

www.aldeyra.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$43M

EPS (Diluted)

-$0.73

Free Cash Flow

-$40M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q4 2025

May 13, 2026

PENDING

Q3 2025

Nov 5, 2025

$0EPS -$0.13

Q2 2025

Aug 7, 2025

$0EPS -$0.16

Q1 2025

May 14, 2025

$0EPS -$0.17

FY 2024

Feb 28, 2025

$0EPS -$0.94

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q4 21	$0	-$61.3K	-$15M
Q1 22	$0	$0	-$16M
Q2 22	$0	$0	-$18M
Q3 22	$0	$0	-$15M
Q4 22	$0	-$66.6K	-$14M
Q1 23	$0	$0	-$17M
Q2 23	$0	$0	-$10M
Q3 23	$0	$0	-$10M
Q4 23	$0	-$66.5K	-$6M
Q1 24	$0	$0	-$9M
Q2 24	$0	$0	-$18M
Q3 24	$0	$0	-$16M
Q4 24	$0	-$64.4K	-$17M
Q1 25	$0	$0	-$10M
Q2 25	$0	$0	-$10M
Q3 25	$0	$0	-$8M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 21	-$12M	-$12M
Q1 22	-$13M	-$13M
Q2 22	-$20M	-$20M
Q3 22	-$13M	-$13M
Q4 22	-$11M	-$11M
Q1 23	-$9M	-$9M
Q2 23	-$13M	-$13M
Q3 23	-$8M	-$8M
Q4 23	$500.4K	$500.4K
Q1 24	-$10M	-$10M
Q2 24	-$13M	-$13M
Q3 24	-$8M	-$8M
Q4 24	-$12M	-$12M
Q1 25	-$12M	-$12M
Q2 25	-$9M	-$9M
Q3 25	-$7M	-$7M

Capital Expenditures

Quarter	CapEx
Q4 21	$0
Q1 22	$16.3K
Q2 22	$0
Q3 22	$2
Q4 22	$0
Q1 23	$2
Q2 23	$4
Q3 23	$0
Q4 23	$0
Q1 24	$0
Q2 24	$0
Q3 24	$0
Q4 24	$0
Q1 25	$0
Q2 25	$0
Q3 25	$4

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 21	—	+61.6%
Q1 22	—	+52.2%
Q2 22	—	+21.8%
Q3 22	—	-4.3%
Q4 22	—	-11.1%
Q1 23	—	+1.9%
Q2 23	—	-41.6%
Q3 23	—	-35.4%
Q4 23	—	-55.5%
Q1 24	—	-44.1%
Q2 24	—	+74.1%
Q3 24	—	+69.0%
Q4 24	—	+171.9%
Q1 25	—	+11.0%
Q2 25	—	-43.5%
Q3 25	—	-50.4%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 21	$984.5K	—
Q1 22	$2M	—
Q2 22	$1M	—
Q3 22	$2M	—
Q4 22	$3M	—
Q1 23	$4M	—
Q2 23	$2M	—
Q3 23	$789.2K	—
Q4 23	-$800.3K	—
Q1 24	$2M	—
Q2 24	$2M	—
Q3 24	$3M	—
Q4 24	$1M	—
Q1 25	$2M	—
Q2 25	$196.6K	—
Q3 25	$3M	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q4 21	$13M	—	$3M
Q1 22	$12M	$4M	—
Q2 22	$15M	$3M	—
Q3 22	$12M	$3M	—
Q4 22	$9M	—	$5M
Q1 23	$11M	$6M	—
Q2 23	$7M	$3M	—
Q3 23	$7M	$3M	—
Q4 23	$4M	—	$2M
Q1 24	$6M	$3M	—
Q2 24	$15M	$3M	—
Q3 24	$12M	$4M	—
Q4 24	$15M	—	$2M
Q1 25	$7M	$3M	—
Q2 25	$9M	$2M	—
Q3 25	$5M	$3M	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 21	$230M	$0	$230M
Q1 22	$159M	$58M	$217M
Q2 22	$121M	$76M	$197M
Q3 22	$129M	$57M	$185M
Q4 22	$144M	$30M	$174M
Q1 23	$165M	$0	$165M
Q2 23	$152M	$0	$152M
Q3 23	$143M	$0	$143M
Q4 23	$143M	$0	$143M
Q1 24	$102M	$31M	$133M
Q2 24	$71M	$49M	$120M
Q3 24	$68M	$45M	$113M
Q4 24	$55M	$47M	$101M
Q1 25	$50M	$40M	$90M
Q2 25	$41M	$41M	$82M
Q3 25	$59M	$16M	$75M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q4 21	58M	-0.0%	+50.0%
Q1 22	58M	+0.5%	+27.8%
Q2 22	58M	+0.0%	+7.4%
Q3 22	58M	+0.3%	+0.8%
Q4 22	59M	+0.2%	+0.9%
Q1 23	59M	+0.4%	+0.8%
Q2 23	59M	+0.0%	+0.8%
Q3 23	59M	+0.3%	+0.9%
Q4 23	59M	+0.3%	+1.1%
Q1 24	59M	+0.4%	+1.1%
Q2 24	59M	0.0%	+1.1%
Q3 24	60M	+0.2%	+0.9%
Q4 24	59M	-0.1%	+0.5%
Q1 25	60M	+0.7%	+0.8%
Q2 25	60M	+0.3%	+1.1%
Q3 25	60M	+0.1%	+1.0%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q4 21	$0	12
Q1 22	$0	12
Q2 22	$0	12
Q3 22	$0	12
Q4 22	$0	15
Q1 23	$0	15
Q2 23	$0	15
Q3 23	$0	15
Q4 23	$0	10
Q1 24	$0	10
Q2 24	$0	10
Q3 24	$0	10
Q4 24	$0	9
Q1 25	$0	9
Q2 25	$0	9
Q3 25	$0	9

Revenue / Employee